According to the World Health Organization (WHO) estimates [1], Hib still causes at least 3 millions cases of serious illness and nearly 386,000 deaths yearly, the vast majority of them in developing countries and therefore with low immunization coverage. WHO recommends the inclusion of Hib vaccination in all routine infant immunization programs with a 3-dose primary schedule with or without a booster dose or 2 primary doses plus a booster dose [2]. At the end of 2007, more than 122 countries have introduced the vaccine into their childhood immunization programs according to WHO [2]. The impact of vaccination on the incidence of invasive Hib infections was a dramatic decrease of more than 95% in the first years after its implementation [3]. In fact, invasive Hib pathologies have practically disappeared in many industrialized countries and their incidence has dropped dramatically in countries where vaccination coverage is satisfactory. It is estimated that 92% of children in industrialized countries are immunized against Hib, while the immunization rate is estimated near 42% in developing countries and 8% in least developed countries mainly in sub-Saharan Africa [1] [4].

In Mali, hospital surveillance of invasive bacterial diseases carried out by the Center for the Development of Vaccines (CVD-Mali) since 2002 has revealed a high incidence of invasive disease due to Haemophilus influenzae type b [5]. The results of this surveillance led to the introduction of the Hib conjugate vaccine into the Expanded Immunization Program in July 2005.

After the introduction of vaccination annual confirmed Hib hospitalizations in infants from 0 to 11 months decreased from 175/100,000 to 44/100,000 and in infants 6 - 7 months from 377/100,000 to 69/100,000, i.e. a decrease of 82% [6]. According to the National Immunization Center of Mali, the Hib vaccination coverage rate was 90% in 2015 [7]. Ten years after the introduction of the Hib vaccine, we thought it appropriate to do a study on invasive bacterial Hib infections in pediatric environment.

Our study was carried out in the pediatrics department of the UH-GT, a tertiary hospital located in the center of the city of Bamako.

This was a retrospective and descriptive study involving children aged from 0 to 180 months, admitted for a confirmed bacterial infection by Hib between January 1, 2017 to December 31, 2018 (i.e. 24 months).

Included were any patient with confirmed bacterial Hib infection either in cerebro spinal fluid (CSF), blood culture, or any other sample. This is a comprehensive sample of all children 0 to 180 months of age hospitalized during the study period for confirmed Haemophilus influenzae b infection. We developed a survey formulary that allowed us to collect data from hospitalization records, the inclusion register of participants in the pediatric unit of the Center for Vaccin Development (CVD) and the laboratory results register.

The variables studied were: epidemiological, clinical, biological, therapeutic and evolutionary characteristics.

Data analysis and processing was performed on SPSS software version 20.0. Chi-square and Fisher statistical tests were used. Data confidentiality was respected.

During the study period 33 cases of confirmed invasive infections with Haemophilus influenzae type b were identified out of a total hospitalization of 16,228 giving a frequency of 0.2%. Sow et al. [6] in Mali reported a decrease of incidence and hospitalization due to Hib after the introduction of the pentavalent vaccine in July 2005 with hospitalizations going from 377/10⁵ to 69/10⁵. In Egypt, the number of confirmed cases of Hib meningitis is 23/100,000 among children under 5 years [8]. Also David W et al. [9], reported that the Haemophilus influenzae type b conjugate vaccine reduced the annual number of cases of H. influenzae type b meningitis in children. Although the prevalence of Haemophilus influenzae infection significantly decreased, 21.21% of the children did not receive any vaccine according to the vaccination schedule. In 2007, Haemophilus influenzae B vaccine coverage was 96.7% in Burkina Faso [10], 68% in the Gambia [11]. This situation urges health authorities to strenghten their efforts to immunize children who still miss the immunization program (Table 1).

Classically the authors divide the ages of children into three groups: less than one year old, one to five years old and more than five years old. We preferred the distribution in less than three months, three months to three years, three years to five years and more than five years. This subdivision is based on the evolution of anti-Hib antibody titers in children (Tables 2-5).

*Programme élargi de vaccination: extendend immunization program.

Others: 1 case of palor and 1 case of anuria.

The 3 - 36 montha age group was the most represented with 72.73%. This age group was largely found by CISSE in Dakar with 92% [12]. These results confirm that Hib meningitis is typically a disease of young children. In addition, they establish the correlation between anti-Hib antibody titers and the frequency of Hib infections in children. Indeed, before three months the child is protected by maternal antibodies. Between three months and three years of age, the child has lost maternal antibodies and his immune system does not produce enough antibodies. Therefore, they are more exposed to infections including Hib. Between the ages of three and five, a child is still protected because his immune system hasprogressive implementation. After five years, antibody titers are at their maximum and its protection is complete in the absence of any immune deficiency [13].

Hib is endemic with periods of recrudescence without significant impact of temperature and rainfall. Indeed, Sow et al. [6], had already reported the non-seasonality of Haemophilus influenzae b infection in Mali. On the other hand, Diawara A. et al. reported that the distribution of the disease was higher during the dry season (November-April) (51.0%) than during the rainy season (May-October) (49.0%) [14].

Camara B. et al. [15] observed that Hib meningitis is encountered throughout the year with a peak occurring between January and March, that is, during the dry and cold season.

In sub sahara Africa, the cold season is very favorable to the expansion of Ear-Nose-Larynx and respiratory infections which are the beds of bacterial meningitis. In addition, the chronic carriage of Hib in the nasopharynx of children would explain the onset of the disease throughout the year.

The peak at the start of the dry season in the tropics could be attributed to the sudden change in physiological mechanisms of adaptation to the cold.

Bacterial meningitis was the most common diagnosis (78.79%), followed by sepsis (9.09%), and pneumonia (6.06%). The predominance of meningeal localization of Hib has been reported by several authors [8] [16] [17].

Despite the administration of antibiotics in our health structures due to insufficient laboratory tests, all cases of meningitis were diagnosed by culture of the CSF. Pederson et al. [18] in Denmark confirm our result with 100% of cases of meningitis confirmed by CSF culture.

We recorded a lethality of 21.21% less than that reported by Cissé et al. in Senegal [12], Tall F et al. in Burkina Faso [19] with 32.7% and 26% respectively.

Our high lethality could be explained by: the delay in diagnosis, the weakness of the technical equipement (lack of intensive care units) and co-morbidities (malnutrition in 33.33% of cases, HIV infection in 6% of cases).

The authors declare no conflicts of interest regarding the publication of this paper.

Maiga, B., Diakité, A.A., Sacko, K., Sylla, M., Maiga, M., Cissé, M.E., Dembélé, A., Traoré, F., Konaté, D., Diakité, F.L., Sidibé, L., Doumbia, A.K., Coulibaly, O., Togo, P., Touré, A., Traoré, K., Maiga, L., Ibrahim, A., Diall, H., Doumbia, A., Konare, H., Sagara, S., Niakaté, M. and Cissouma, A. (2021) Invasive Haemophilus influenzae Type b (Hib) Infections in Children in the Pediatric Department of the University Hospital Gabriel Touré (UH-GT). Open Journal of Pediatrics, 11, 100-107. https://doi.org/10.4236/ojped.2021.111009